A Multicenter Open-label Study Investigating the Pharmacokinetics and Safety of Aripiprazole IM Depot Formulation (OPC-14597 IMD) During Repeated Administration by Injection Into the Deltoid Muscle in Patients With Schizophrenia

Phase 1

Completed

Conditions: Schizophrenia

Interventions: Drug: OPC-14597 IMD

Registration Number: NCT02220712

Lead Sponsor: Otsuka Pharmaceutical Co., Ltd.

Brief Summary: To assess the pharmacokinetics and safety of aripiprazole intra-muscular (IM) depot formulation in patients with schizophrenia after repeated administration by injection into the deltoid muscle for a total of 5 doses of 400 mg in 4-week intervals

Detailed Description: Not available

Recruitment & Eligibility

Status: COMPLETED

Sex: All

Target Recruitment: 17

Inclusion Criteria

Patients with a diagnosis of schizophrenia as defined by Diagnostic and Statistical Manual (DSM)-IV-Text Revision (TR) (295.30, 295.10, 295.20, 295.90, 295.60)
Patients who have provided written informed consent by themselves (If the patient is a minor, written consent from a legal representative must be obtained in addition to the patient's own written informed consent.)
Patients, both male and female, aged 18 years or older, but younger than 65 years, at the time of obtaining informed consent
Patients with a body mass index of 18.5 or higher and lower than 35.0
Patients whose mental condition is stable or well maintained for 2 weeks or more without any change to dosage regimen for their non-aripiprazole oral atypical antipsychotic monotherapy prior to obtaining informed consent
Patients who have received aripiprazole in the past

Exclusion Criteria

Patients diagnosed as having a mental disorder other than schizophrenia, as defined by DSM-IV-TR criteria.
Patients with a history or complication of diabetes.
Patients with hepatic, renal, cardiac, or hematopoietic disorders.
Female patients who are pregnant or lactating, who may possibly be pregnant, who wish to become pregnant, or male patients whose partner wishes to become pregnant.
Patients who have a drug allergy or drug hypersensitivity
Patients for whom clozapine has been ineffective, patients who have responded only to clozapine, or patients who are currently being treated with clozapine.
Patients with a complication of Parkinson's Disease (excluding drug-induced Parkinsonism).
Patients with a history or a complication of neuroleptic malignant syndrome, rhabdomyolysis, tardive dyskinesia, paralytic ileus or water intoxication.
Patients with a history or a complication of psychological or behavioral abnormalities associated with use of psychoactive substances (abuse of alcohol, narcotics, or organic solvent, etc).
Patients with a history or a complication of suicide attempt or self-injury within 52 weeks prior to obtaining informed consent.
Patients with a history of or a complication of convulsive disorder such as epilepsy.
Patients with a history of or a complication of organic brain disorder including cerebrovascular disease.
Patients with a history or a complication of granulocytopenia or agranulocytosis.
Patients who have received electro-convulsive therapy (ECT) within 12 weeks prior to obtaining informed consent.

Study & Design

Study Type: INTERVENTIONAL

Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Drug: OPC-14597 IMD	OPC-14597 IMD	-

Primary Outcome Measures

Name	Time	Method
OPC-14597 Plasma Concentration 672 Hours Postdose Following Multiple Administration of OPC-14597 IMD Injections	672 hours postdose of the first, second, third, fourth, and fifth IMD injections

Secondary Outcome Measures